Newsroom
News from UCLB
AstronauTx secures investment from UCL Technology Fund to further new approaches to dementia therapeutics
London, UK 24 March, 2020 AstronauTx Ltd, a biotech company developing new medicines designed to restore the normal behaviour of ...
Freeline Therapeutics appoints new Chief Medical Officer
The biotechnology company focused on developing curative gene therapies for chronic systemic diseases has announced the appointment of Julie Krop ...
Professor Sergio Quezada appointed as Chief Scientific Officer of Achilles Therapeutics
Achilles Therapeutics has announced the appointment of Professor Sergio Quezada of the UCL Cancer Institute as Chief Scientific Officer with ...
Professor Bobby Gaspar named as the new CEO of Orchard Therapeutics
Congratulations to Professor Bobby Gaspar of the UCL Great Ormond Street Institute of Child Health who has been named the ...
UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, London
• PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR • AAV-RPGR is the only ...
BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review ...
Two UCLB spinout companies announced winners at the 2019 SEHTA MedTech Business Awards
UCLB spinout companies Odin Vision and Echopoint Medical received awards at the 2019 SEHTA MedTech Business Awards on Thursday 6 ...
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD BOSTON ...
SmartTarget Ltd announces sale of technology to Miami-based Intuitive Fusion LLC.
London, 24 January 2020 SmartTarget Ltd, a spinout company of UCL which successfully brought to market image fusion technology allowing accurate ...
UCLB launches applications for social challenge with London Borough of Camden
Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? ...
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure
DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to ...
UCL developed FVIII gene therapy treatment shows excellent results
A FVIII gene therapy treatment, developed by world leading gene therapy expert, Professor Amit Nathwani at UCL has shown positive ...
Syncona makes a further $80 million commitment to Freeline
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has ...
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent ...
